Glutathione Injection: Evidence, Safety Signals and How to Check a Product in Pakistan

In short: glutathione is an important molecule, and injected glutathione has been studied in small trials, mainly for nerve damage from platinum chemotherapy and in one pilot in a movement disorder. We found no adequate randomised trial of injections for cosmetic skin-tone purposes, a regulator elsewhere has warned against the practice, and in our reading an injectable glutathione product may be imported and supplied in Pakistan only if DRAP has registered it, subject to narrow statutory exemptions. The practical question is less “does it work” than “is this product registered, and who is accountable for it”.

Dawn reported in August 2026 that glutathione drips, used for cosmetic skin-tone purposes, are among the most sought-after aesthetic treatments in Pakistan. In our reading, an injectable may be imported and supplied in Pakistan only if DRAP has registered it, subject to narrow statutory exemptions. The evidence position is less settled, and it is the subject of most of this article.

It is general information from public sources for healthcare professionals, not medical or legal advice, and it makes no claim about any IVIXIR product.

What glutathione is, and what an injection does

Glutathione is a tripeptide of glutamate, cysteine and glycine, and the main intracellular antioxidant of human cells; the Knowledge Base describes glutathione together with its building blocks cysteine and glycine. The body synthesises it from those amino acids.

What an injection does to blood levels has been measured. In a study of 10 healthy volunteers (Aebi et al., 1991), plasma glutathione rose steeply during infusion and then fell rapidly, while urinary excretion of glutathione and cysteine rose sharply. Plasma cysteine also rose, but total plasma cyst(e)ine fell, which the authors read as cells taking up more cysteine. That is pharmacokinetics: it shows that infused glutathione is cleared quickly and may supply cysteine to tissues. It does not show, by itself, a lasting rise in tissue glutathione or any clinical benefit.

What the trials have tested

Controlled human data on glutathione given by injection or infusion are confined to a few settings, summarised in the table. Disease names appear only as the conditions in which studies were done; none is a claim about any product.

The first row has the longest history. Cascinu and colleagues (1995) randomised 50 patients receiving cisplatin-based chemotherapy to glutathione or placebo infusions and found less neurotoxicity in the glutathione group; a later Cochrane review assessed the glutathione trials as a group and could not conclude protection on objective measures. These studies took place in specialist oncology settings, under protocols written for patients whose treatment carries a defined risk of nerve damage. In our reading they explain why glutathione appears in the literature on injection, and they do not extend to elective use in well people.

Two cautions about the table. The studies in the first two rows tested glutathione in people with defined diagnoses under physician supervision, with protocols and monitoring that a cosmetic clinic does not replicate. And “small” has a precise meaning here: in the most thoroughly studied setting, the Cochrane pooling covers 387 participants across seven trials, judged mostly on subjective scales.

Reading a claim about glutathione

Three questions sort most claims. First, which route was studied: by mouth, on the skin or intravenous? Results do not transfer between them, and the controlled cosmetic trials we found concern the first two. Second, in whom: a trial in patients receiving platinum chemotherapy says little about a well adult, and a pilot in 21 people with a movement disorder says little about either. Third, which outcome: a rise in a blood level, a change on a rating scale, or something a patient would notice and value? A claim that cites a blood level is a pharmacokinetic claim, whatever its headline says. A claim with no citation, or one that cites only a seller's own leaflet, has not yet reached the question.

Safety signals

There is no complete side-effect profile for elective glutathione infusions in well people, because the trials were not designed to build one. What exists is a set of cautions.

A regulator's advisory. In July 2019 the Philippines FDA (Advisory No. 2019-182) stated that it had approved no injectable glutathione product for cosmetic use, noted that no published trials had evaluated it for that purpose, and warned of possible liver, kidney and nervous-system toxicity, severe skin reactions and infection risk when infusions are given in non-sterile settings. GMA News reported the advisory.

The setting. The setting matters as much as the molecule. Intravenous catheters carry infection risks that established guidelines address through aseptic technique and site care (US CDC, 2011), and an infusion given outside a licensed, supervised setting removes those safeguards. In Pakistan, press reports from 2025 and 2026 describe commissions sealing aesthetic clinics that lacked qualified practitioners or licences; our article on IV drip therapy in Pakistani clinics summarises them.

The product. The DRAP Act prohibits importing, manufacturing for sale or selling therapeutic goods that are spurious, counterfeit, misbranded, adulterated or substandard, as well as those that are not registered. An unregistered ampoule has passed no DRAP review of its quality or labelling, and no registration holder in Pakistan is accountable for it.

Is the product on offer registered with DRAP? How to check

“Imported” is not a registration status. In our reading, an injectable glutathione product offered for use in patients falls within the DRAP Act's definition of a drug, which covers substances used for the treatment, mitigation, prevention or diagnosis of disease and for correcting or modifying organic functions. Schedule II-A of the Act prohibits importing or selling a therapeutic good that is not registered. The penalty under Schedule III is imprisonment of three to ten years and a fine that may extend to ten lakh rupees, although the Drug Court may award a shorter sentence for special reasons. Whether a particular clinic's activity falls within those provisions is a question for its legal adviser.

Five checks make a difference:

1. Ask for the registration number, with the registered name, strength and holder, and confirm that it belongs to this product, this strength and this dosage form, not to another product or an oral or cosmetic one.
2. Look it up. DRAP publishes a searchable list of registered products (Registered Product Data at eapp.dra.gov.pk), which DRAP itself calls provisional, so also ask for the Certificate of Registration (Form 6), valid for five years unless cancelled or suspended.
3. Match the pack. Name, manufacturer, strength, batch number and expiry on the carton and ampoule should agree with the registration and the invoice. Selling a therapeutic good under a name other than its registered name is a separate offence under Schedule III.
4. Check the chain. The importer's Drug Sale Licence, the authorisation from the manufacturer, and a supply that comes from that importer or its distributor, not from an individual or a social media page.
5. Ask for the batch certificate of analysis and the storage and transport conditions.

Red flags include: no registration number; packs marked for export only or labelled only in a foreign language; offers made through social media pages or messaging apps; a seller who cannot name the importer; and vials handed to clinics as samples (the Act, in Schedule II-C, allows distribution of therapeutic goods as samples only on prescribed conditions). We have not audited DRAP's list for glutathione products, and registration status can change, so check the list yourself on the day.

Where EFBA stands

This article is general information. Nothing in it is a claim about any IVIXIR product. IVIXIR products do not currently hold a DRAP registration, and IVIXIR products are supplied in Pakistan only after DRAP registration through a licensed importer; samples are not offered via this website. Licensed importers who would like to discuss registration can read about the registration and distribution partnership; clinics and physicians can ask about the formulations through the quote request form.